MustGrow Biologics Corp. (TSXV:MGRO)
Canada · Delayed Price · Currency is CAD 0.5000
-0.0500 (-9.09%)
May 12, 2026, 3:59 PM EST
MustGrow Biologics Earnings Call Transcripts
Fiscal Year 2025
-
2025 sales fell short due to NexusBioAg underperformance, but TerraSante sales surged 377% year-over-year. Focus is now on expanding TerraSante in the U.S. and globally, with improved margins expected in 2026 and cash flow breakeven targeted for 2027.
-
Q3 2025 saw seasonally low sales and no TerraSate revenue due to inventory shortages, but gross margin improved to 22%. Strong demand for TerraSate and new product launches are expected to drive a robust Q4 and a positive outlook for 2026, with break-even targeted next year.